Yan L, Gong G X, Scholz P M, Tse J, Weiss H R
Department of Physiology and Biophysics, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway 08854-5635, USA.
Res Exp Med (Berl). 1998 Oct;198(3):123-32. doi: 10.1007/s004330050096.
We tested the hypothesis that the negative metabolic effects of elevating cyclic GMP act through inhibition of L-type calcium channels in quiescent cardiac myocytes. The steady state O2 consumption (VO2) of ventricular myocytes, isolated from hearts of New Zealand white rabbits, was measured in a glass chamber using Clark-type oxygen electrodes. The cellular cyclic GMP levels were determined by radioimmunoassay at baseline with either 0.5 mM or 2.0 mM of Ca2+, sodium nitroprusside at increasing concentration (10(-8),(-6),(-4) M) with and without pretreatment by BAY K8644 10(-5) M (L-type Ca2+ channel activator) in 0.5 mM Ca2+, or nitroprusside with and without pretreatment with nifedipine 10(-4) M (L-type Ca2+ channel blocker) in 2.0 mM Ca2+. In the 0.5 mM Ca2+ medium, basal VO2 was 459 +/- 104 (nl O2/min per 10(5) myocytes) with a corresponding cyclic GMP level of 112 +/- 23 (fmol/10(5) myocytes). With nitroprusside 10(-4) M, VO2 was decreased to 285 +/- 39 and cyclic GMP level was significantly elevated to 425 +/- 128. In the same medium, VO2 was slightly increased by BAY K8644 10(-5) M while the cyclic GMP level did not change. With BAY K8644 10(-5) M, nitroprusside 10(-4) M decreased VO2 and increased cyclic GMP to a level which was similar to cells treated with nitroprusside alone. In the 2.0 mM Ca2+ medium, the basal VO2 and cyclic GMP were 518 +/- 121 and 137 +/- 24. In the presence of nitroprusside 10(-4) M, VO2 was decreased to 295 +/- 49 and cyclic GMP was increased to 454 +/- 116. In the same medium, nifedipine 10(-4) M significantly decreased VO2, while the cyclic GMP level was comparable to the baseline. After nifedipine 10(-4) M, nitroprusside 10(-4) M decreased VO2 and increased cyclic GMP to levels which were similar to control. Therefore, in quiescent cardiac myocytes, the negative metabolic effects associated with cyclic GMP were not primarily mediated through inhibition of L-type Ca2+ channels.
环磷酸鸟苷(cGMP)升高所产生的负面代谢效应是通过抑制静态心肌细胞中的L型钙通道来实现的。使用克拉克型氧电极在玻璃室中测量从新西兰白兔心脏分离出的心室肌细胞的稳态耗氧量(VO2)。通过放射免疫分析法在基线时测定细胞内cGMP水平,分别在0.5 mM或2.0 mM Ca2+条件下,用浓度递增的硝普钠(10(-8)、10(-6)、10(-4) M)处理,在0.5 mM Ca2+条件下,有或没有用10(-5) M BAY K8644(L型钙通道激活剂)预处理;或者在2.0 mM Ca2+条件下,有或没有用10(-4) M硝苯地平(L型钙通道阻滞剂)预处理后再用硝普钠处理。在0.5 mM Ca2+培养基中,基础VO2为459±104(每10(5)个肌细胞每分钟消耗nl O2),相应的cGMP水平为112±23(fmol/10(5)个肌细胞)。使用10(-4) M硝普钠时,VO2降至285±39,cGMP水平显著升高至425±128。在相同培养基中,10(-5) M BAY K8644使VO2略有增加,而cGMP水平未改变。使用10(-5) M BAY K8644时,10(-4) M硝普钠降低了VO2并使cGMP增加到与单独用硝普钠处理的细胞相似的水平。在2.0 mM Ca2+培养基中,基础VO2和cGMP分别为518±121和137±24。在存在10(-4) M硝普钠的情况下,VO2降至295±49,cGMP增加到454±116。在相同培养基中,10(-4) M硝苯地平显著降低了VO2,而cGMP水平与基线相当。在用10(-4) M硝苯地平处理后,10(-4) M硝普钠降低了VO2并使cGMP增加到与对照相似的水平。因此,在静态心肌细胞中,与cGMP相关的负面代谢效应并非主要通过抑制L型Ca2+通道介导。